Park Ridge, United States
Neurolixis, founded in 2011, is a promising biopharmaceutical company based in the United States. With a mission encapsulated by its slogan, "New treatments for central nervous system disorders," the company is dedicated to advancing the field of biotechnology by focusing on novel drug discoveries. Its primary areas of interest include movement disorders, autism spectrum disorders, depression, and pain treatment.
The company operates within the Biopharma, Biotechnology, and Health Care industries, showcasing its versatility and commitment to addressing pressing medical needs. Despite its early and small $15.00K seed round investment on 18 July 2013, Neurolixis holds potential for future growth. However, the absence of disclosed investors from this round might raise questions about its funding visibility or network connections. As Neurolixis continues to innovate, potential investors should monitor its upcoming milestones and breakthroughs.
